Tekla Ebit Per Revenue from 2010 to 2024

HQL Stock  USD 14.26  0.13  0.92%   
Tekla Life Ebit Per Revenue yearly trend continues to be quite stable with very little volatility. The value of Ebit Per Revenue is projected to decrease to -0.21. From the period between 2010 and 2024, Tekla Life, Ebit Per Revenue regression line of its data series had sample variance of  4.99 and sample variance of  4.99. View All Fundamentals
 
Ebit Per Revenue  
First Reported
2010-12-31
Previous Quarter
(0.20)
Current Value
(0.21)
Quarterly Volatility
2.23486754
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tekla Life financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Life's main balance sheet or income statement drivers, such as Depreciation And Amortization of 183.4 K, Interest Expense of 0.0 or Total Revenue of 28.4 M, as well as many indicators such as Price To Sales Ratio of 15.52, Dividend Yield of 0.0 or PTB Ratio of 0.92. Tekla financial statements analysis is a perfect complement when working with Tekla Life Valuation or Volatility modules.
  
Check out the analysis of Tekla Life Correlation against competitors.

Latest Tekla Life's Ebit Per Revenue Growth Pattern

Below is the plot of the Ebit Per Revenue of Tekla Life Sciences over the last few years. It is Tekla Life's Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Life's overall financial position and show how it may be relating to other accounts over time.
Ebit Per Revenue10 Years Trend
Slightly volatile
   Ebit Per Revenue   
       Timeline  

Tekla Ebit Per Revenue Regression Statistics

Arithmetic Mean(1.03)
Coefficient Of Variation(216.19)
Mean Deviation1.78
Median(0.21)
Standard Deviation2.23
Sample Variance4.99
Range7.1507
R-Value0.67
Mean Square Error2.94
R-Squared0.45
Significance0.01
Slope0.34
Total Sum of Squares69.92

Tekla Ebit Per Revenue History

2024 -0.21
2023 -0.2
2022 -0.22
2021 1.01
2020 0.98
2019 0.99
2018 1.02

About Tekla Life Financial Statements

Tekla Life investors utilize fundamental indicators, such as Ebit Per Revenue, to predict how Tekla Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Ebit Per Revenue(0.20)(0.21)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Tekla Life Sciences is a strong investment it is important to analyze Tekla Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tekla Life's future performance. For an informed investment choice regarding Tekla Stock, refer to the following important reports:
Check out the analysis of Tekla Life Correlation against competitors.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.425
Dividend Share
1.3
Earnings Share
1.34
Revenue Per Share
0.134
Quarterly Revenue Growth
0.07
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.